Compare SER & HYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SER | HYFT |
|---|---|---|
| Founded | 2017 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.4M | 56.5M |
| IPO Year | 2024 | 2017 |
| Metric | SER | HYFT |
|---|---|---|
| Price | $1.44 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $9.50 | $4.33 |
| AVG Volume (30 Days) | 71.2K | ★ 252.1K |
| Earning Date | 11-24-2026 | 12-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $130,000.00 | N/A |
| Revenue This Year | N/A | $12.86 |
| Revenue Next Year | N/A | $22.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.14 | N/A |
| 52 Week Low | $1.14 | $0.98 |
| 52 Week High | $4.26 | $3.00 |
| Indicator | SER | HYFT |
|---|---|---|
| Relative Strength Index (RSI) | 31.92 | 34.19 |
| Support Level | $1.38 | N/A |
| Resistance Level | $2.13 | $1.50 |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 17.73 | 12.47 |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.